Can China retain its API sourcing appeal?
February 2010
Chinese companies are gearing up to supply newer pharmaceutical ingredients to the regulated markets of the West.
For many years, China has been an important supplier of intermediates and older off-patent molecules. Robert Kennedy's analysis, published in the year-end Scrip 100 issue, reveals that it has integrated itself into the global supply chain for both innovator pharma and generics companies, and is no longer merely a low-cost threat. A striking number of Chinese companies are now gearing up to supply newer molecules, and are slowly becoming involved in the development of non-infringing processes in support of patent challenges.
Additional information
Can China retain its API sourcing appeal? - read the full report (PDF)
Was this article useful?
Register now to receive KnowledgeLink direct to your mailbox every two months.
Download a PDF of all
February 2010's
KnowledgeLink articles